← Human Trials & Peer-Reviewed Studies
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Plain-language guide to PMID 28385659 (2017): double-blind randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 28385659
- Journal
- The lancet. Diabetes & endocrinology
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Ahrén B et al. (7 authors)
- DOI
- 10.1016/S2213-8587(17)30092-X
- Registered trial
- NCT01930188
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide in this randomized controlled trial publication.
Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for once-weekly subcutaneous administration, in development for treatment of type 2 diabetes.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.
The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.
More than one site took part, so the participants came from several places.
The researchers did a 56-week, phase 3a, randomised, double-blind, double-dummy, active-controlled, parallel-group, multinational, multicentre trial (SUSTAIN 2) at 128 sites in 18 countries.
Safety endpoints included adverse events and hypoglycaemic episodes.
This trial is registered with ClinicalTrials.gov, number NCT01930188.
What Was Measured
The subject headings attached to it are Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Metformin, Sitagliptin Phosphate, Thiazolidinediones and Semaglutide.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2017 (The lancet. Diabetes & endocrinology), a journal based in England.
More context: the Semaglutide compound page.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.